SEONGDONG-GU, SEOUL, SOUTH KOREA, January 5, 2023 / EINPresswire.com / -- MDimune Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), ...
GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and formulation capabilities with the launch of a GMP-like mRNA manufacturing service, ...
This collaboration reinforces HRV's broader mission of building an AI-enabled, asset-light pharmaceutical platform, and MetroChem's emergence as a preferred partner for complex and specialty API ...
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal ...
TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation (President: Kenji Sukeno) is to invest a total of 3.2 billion yen on its CDMO *1 sites in the U.S.A. and the U.K. in order to accelerate the expansion of ...
GAINESVILLE, Fla., May 28, 2020 /PRNewswire/ -- Arranta Bio ("Arranta"), the leading microbiome contract development and manufacturing organization (CDMO), today announced completion of its process ...
The launch of the GMP PSXi013 iPSC Master Cell Bank marks a pivotal moment in Pluristyx's ongoing mission to accelerate the development of stem cell therapies. By providing a high-quality, low-passage ...
CRISPR-Cas9 is one of the most commonly leveraged non-viral editing tools to engineer cells for therapeutics applications. It is a nuclease-based genome editing system which has seen exponential ...
Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...
Almac is pleased to announce the expansion of our drug product Pharmaceutical Development services with the creation of a new non-GMP formulation development facility and two new analytical ...
GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, and ...
NEW YORK--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq: CLLS) today announced that a series of three production runs of UCART19, its lead TALEN ® ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback